Takeda drops pioglitazone/metformin extended release combo in the EU
This article was originally published in Scrip
Takeda has withdrawn an EU marketing authorisation application for an extended release version of its oral antidiabetic product Competact, and has decided to discontinue the further development in the EU of this form of the fixed dose combination.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.